Takeda’s investigational TAK-881 met the primary PK endpoint in the IgGNITE PID trial, halving infusion volume and shortening administration time versus HYQVIA.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
Takeda reported detailed results from the pivotal Phase 2/3 IgGNITE trial (TAK-881-3001, NCT05755035) on October 14, 2026, evaluating investigational TAK-881 in patients with primary immunodeficiency disease (PID). Presented in two late-breaking posters at the 2026 meeting of the European Society for Immunodeficiencies (ESID), the results showed pharmacokinetic (PK) comparability with HYQVIA in participants aged 16 years and older. TAK-881 also delivered the same immunoglobulin (IG) dose in 50% less volume, reducing median infusion duration.
If approved, TAK-881 could become the first hyaluronidase-facilitated subcutaneous immunoglobulin 20% (SCIG 20%) therapy for PID administered every three to four weeks.
About Primary Immunodeficiency Disease
PID comprises more than 550 rare, chronic disorders involving deficiencies or dysfunctions of the immune system. Many patients require lifelong IG replacement to maintain protective antibody levels and reduce infections. Although established therapies provide immune protection, infusion volume, duration and frequency can contribute to treatment burden.
TAK-881 and the IgGNITE Study Design
TAK-881 combines human plasma-derived IG 20% with recombinant human hyaluronidase (rHuPH20), which facilitates the dispersion and absorption of immunoglobulin in subcutaneous tissue, allowing larger volumes to be administered at a single site.
The open-label Phase 2/3 trial enrolled patients aged two years and older with PID who had previously received IG therapy. Participants aged 16 years and older entered a randomized crossover comparison of TAK-881 and HYQVIA, an established facilitated SCIG 10% therapy, at the same IG dose and dosing interval for up to 51 weeks. Participants aged two to under 16 years received TAK-881 in a separate single-arm cohort for up to 27 weeks.
The primary endpoint was PK comparability based on IgG exposure. Secondary assessments included steady-state PK parameters, infusion characteristics, infections, safety and tolerability.
Key Clinical Findings
Pharmacokinetic comparability
TAK-881 met the primary endpoint, demonstrating equivalent IgG exposure to HYQVIA. Geometric mean trough IgG concentrations were 11.7 g/L with TAK-881 and 11.9 g/L with HYQVIA, remaining above accepted protective thresholds reported by the company.
The primary endpoint supports comparable systemic IgG exposure under the study conditions. It does not establish superior efficacy over HYQVIA.
Lower infusion volume and shorter administration
At an equivalent bodyweight-adjusted IG dose, TAK-881 reduced total infusion volume by 50%. Median infusion duration decreased from 132 to 75.8 minutes with one infusion site, a reduction of 56.2 minutes (42.6%). With two sites, median duration decreased from 86 to 58.3 minutes, a reduction of 27.7 minutes.
These findings suggest that the higher-concentration formulation could reduce administration time and potentially the number of infusion sites required. Both outcomes may be relevant for patients receiving long-term replacement therapy.
Infection outcomes
Descriptive analyses reported annualized infection rates of 2.62 (95% confidence interval [CI], 1.75–3.76) with TAK-881 and 2.73 (95% CI, 1.85–3.86) with HYQVIA. The annualized serious bacterial infection rate with TAK-881 was 0.0558 (95% CI, 0.0197–0.121). No acute serious bacterial infections were reported during HYQVIA treatment.
These findings are consistent with maintained immune protection, although the secondary analyses do not establish statistical equivalence in infection outcomes.
Safety and tolerability
Treatment-emergent adverse events occurred in 23 of 41 participants (56.1%) receiving TAK-881 and 19 of 38 (50.0%) receiving HYQVIA. Reported events were mild to moderate, with no TAK-881-related serious adverse events or Grade 3 or higher treatment-emergent adverse events. Nine of 43 randomized participants (20.9%) discontinued across both treatment periods; no discontinuation was attributed to a TAK-881-related adverse event.
Long-term safety continues to be evaluated in the TAK-881-3002 extension study.
Regulatory Outlook
Takeda expects to submit applications for TAK-881 in the United States, European Union and Japan during fiscal year 2026. The product remains investigational and has not been approved by any regulator.
Clinical Interpretation
IgGNITE identifies reduced infusion volume and shorter administration time as the clearest potential advantages of TAK-881 over HYQVIA, while meeting the primary PK endpoint. However, infection and safety findings were descriptive, and the open-label crossover involved a limited number of participants. The 20.9% discontinuation rate also warrants consideration when interpreting the results. Because the reported findings concern patients previously treated with IG, they do not establish outcomes in patients initiating replacement therapy. Results from the pediatric cohort and longer-term safety assessments remain important evidence gaps. The findings support further regulatory evaluation, but do not establish improved adherence, quality of life or superiority over other IG treatment options.
Reference
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026, Takeda, 14 October 2026
A Study About How TAK-881 is Processed by the Body and Side Effects in People with Primary Immunodeficiency Diseases, ClinicalTrials.gov ID NCT05755035
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.